Psychedelic medicine (New Rochelle, N.Y.)最新文献

{"title":"Exploring Gender-Themed Lysergic Acid Diethylamide Experiences: A Subreddit Analysis.","authors":"Rahul Katkar, Ashley M Perez, Murat Altinay, Brian S Barnett","doi":"10.1089/psymed.2024.0025","DOIUrl":"10.1089/psymed.2024.0025","url":null,"abstract":"<p><strong>Background and aims: </strong>Gender-themed lysergic acid diethylamide (LSD) experiences have been documented anecdotally but not yet studied systematically. This study aimed to explore such experiences using data from Reddit to better understand their nature and potential therapeutic implications.</p><p><strong>Methods: </strong>In this retrospective observational study, posts and comments on the \"r/LSD\" subreddit reporting gender-themed LSD experiences were analyzed. Posts containing terms related to gender identity, including \"gender,\" \"transgender,\" and \"trans,\" were reviewed and coded using inductive and deductive thematic approaches.</p><p><strong>Results: </strong>Of 94 unique anecdotes, 47.9% of authors identified as non-cisgender at time of LSD use, with most describing experiences that enhanced gender-identity related self-acceptance (80%); 17.0% of authors were gender questioning at the time of LSD use, and most (93.8%) reported clarifying effects of LSD. Fifteen authors (16.0%) reported potential effects of LSD on gender transitioning or plans to transition. A notable minority of the 24 authors identifying as cisgender at time of LSD use (41.7%) explored non-cisgender identities during their LSD experiences, while 29.2% reported their LSD experience introduced a non-cisgender identity for the first time that persisted post-LSD. Challenging experiences were reported by 17.0% of authors, and 11.1% of non-cisgender authors reported LSD experiences that decreased gender identity-related self-acceptance.</p><p><strong>Conclusions: </strong>Our findings suggest LSD may support the exploration and acceptance of gender identity in certain individuals, highlighting a potential role in treating gender dysphoria. They also raise important questions about the need for addressing possible LSD-induced gender identity changes during the informed consent process of clinical trials. Given the fragmentary nature of social media data and challenges in analyzing it, these findings should be confirmed with surveys and prospective observational studies.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 2","pages":"81-92"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Psychedelics for Unmet Needs in Women's Reproductive Health.","authors":"Sara Shoar, Alissa Bazinet, Chaitra Jairaj","doi":"10.1089/psymed.2024.0033","DOIUrl":"10.1089/psymed.2024.0033","url":null,"abstract":"<p><strong>Background: </strong>In recent years, there has been a resurgence in research exploring the therapeutic potential of psychedelics for treating mental health disorders, coinciding with increasing psychedelic use and changing legal landscapes in the United States and globally. Despite these shifts, there remains a notable gap in understanding related to the safety of psychedelic use during critical stages of the female reproductive cycle, including menstruation, pregnancy, postpartum, breastfeeding, and menopause.</p><p><strong>Methods: </strong>This narrative mini-review provides a brief summary of recently published articles in this evolving therapeutic landscape and discusses critical public health implications for addressing psychedelic use for women's reproductive health.</p><p><strong>Results: </strong>Studies have uncovered notable sex differences in users' subjective and physiological experiences of psychedelics. Interactions between psychedelics' mechanisms of action and female hormones suggest opportunities for addressing symptoms of menstruation, sexual dysfunction, chronic pelvic pain, menopause, and postpartum depression (PPD). Women in indigenous communities have traditionally used psychedelics as important components of healing rituals. Yet, potential risks associated with psychedelic use during the reproductive years, specifically during gestation and breastfeeding, underscore the importance of caution and informed decision-making.</p><p><strong>Conclusion: </strong>While there is therapeutic potential for psychedelics in women's reproductive health issues, comprehensive research pertaining to women is lacking. While rigorous scientific inquiry into the safety, efficacy, and mechanisms of action of psychedelics in women's health is paramount, public health messaging should dispel myths and promote risk reduction strategies. Collaboration with indigenous communities and vulnerable populations can enrich understanding and ensure culturally sensitive approaches. Through enhanced research and collaboration, psychedelics can be explored to potentially address unmet needs and enhance women's well-being across diverse reproductive contexts. Existing guidance fails to focus on recommendations for women, highlighting the need for harm reduction strategies.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 2","pages":"113-120"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.","authors":"Haley Maria Dourron, Melissa Bradley, Otto Simonsson, Heith Copes, Daniel Grossman, Ryan Andrew Shallcross, Peter S Hendricks","doi":"10.1089/psymed.2024.0036","DOIUrl":"10.1089/psymed.2024.0036","url":null,"abstract":"<p><strong>Background: </strong>Prior research examining the associations between psychedelic use and general psychotic symptoms has yielded mixed findings. However, no studies have investigated the relationships between psychedelic use and specific psychotic symptoms, and whether these relationships might differ among those with liability to psychosis, namely those with a history of psychotic or bipolar disorders.</p><p><strong>Methods: </strong>Using cross-sectional survey data from a purposive sample (<i>n</i> = 548), we first regressed estimated lifetime psychedelic use occasions and personal and family history of psychotic or bipolar disorders on the Magical Ideation Scale, Referential Thinking Scale, Self-Evaluation of Negative Symptoms, and Continuum of Auditory Hallucinations-State Assessment, unadjusted and adjusted for a range of covariates. We then tested the interactions of estimated lifetime psychedelic use occasions with personal and family history of psychotic or bipolar disorders on these same measures, unadjusted and adjusted for the same set of covariates.</p><p><strong>Results: </strong>In unadjusted models, the estimated number of lifetime psychedelic use occasions was robustly associated with less referential thinking, whereas personal and family histories of psychotic and bipolar disorders were each associated with moderately or slightly greater scores on all measures. Covariate-adjusted regression models revealed that the estimated number of lifetime psychedelic use occasions was not associated with any of the measured psychotic symptoms. A personal history of psychotic disorders was associated with moderately greater magical ideation, referential thinking, and auditory hallucinations, whereas a family history of psychotic disorders was associated with slightly greater negative symptoms. Neither personal nor family history of bipolar disorder was associated with any psychotic symptoms. Finally, estimated lifetime psychedelic use occasions interacted only with a personal history of psychotic disorders on one measure, such that auditory hallucinations were less severe as psychedelic use occasions increased among those with a personal history of psychotic disorder; there was no relationship between psychedelic use and auditory hallucinations among those without a personal history of psychotic disorder.</p><p><strong>Conclusion: </strong>Naturalistic psychedelic use may not be associated with psychotic symptoms, even among those with a personal or family history of psychotic or bipolar disorders. Further work probing the risk-benefit profile for people typically excluded from clinical trials involving psychedelics is needed.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 2","pages":"93-102"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensuring Access to Psychedelic-Assisted Therapy in Rural Communities.","authors":"Olivia M Dhaliwal, Lukas Bobak, Brian S Barnett","doi":"10.1089/psymed.2024.0018","DOIUrl":"10.1089/psymed.2024.0018","url":null,"abstract":"<p><p>With several classical psychedelics being designated as breakthrough therapies and the recent review of a New Drug Application for 3,4-Methylenedioxymethamphetamine in the treatment of posttraumatic stress disorder, the likelihood of psychedelic medication becoming approved for clinical use in the United States is high. Psychedelic-assisted therapy (PAT) may have a high demand in rural America, where residents experience higher burdens of morbidity and premature mortality, due to unique social disparities not shared by urban residents. In these rural settings, barriers to accessing PAT include geographic, economic, and cultural factors as well as the preexisting shortage of health care providers. Disparate access to PAT for rural residents in the United States could exacerbate existing rural-urban inequities. Thus far, the potential challenges of implementing PAT in rural communities have not been extensively discussed in the medical literature. In this perspective, we explore notable implementation barriers in the rural setting and propose potential solutions, including the incorporation of PAT into rural health care training programs, leveraging tools for remote care such as teletherapy for PAT preparation and integration sessions, and implementing new models of care and economic incentives to enable rural PAT providers and rural generalists to deliver PAT. Providing PAT in rural areas will require creative approaches to surmount significant obstacles: the potential solutions discussed here may help ensure rural populations are not left behind if psychedelic medicine is reincorporated into clinical practice in the United States.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 2","pages":"66-70"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative Analysis of Views of Psychedelic-Assisted Therapy in Low-Income, Urban, Black Americans.","authors":"Sierra Carter, Grace Packard, Jessica L Maples-Keller","doi":"10.1089/psymed.2024.0015","DOIUrl":"10.1089/psymed.2024.0015","url":null,"abstract":"<p><strong>Introduction: </strong>Black Americans are significantly underrepresented in psychedelic trials despite significant mental health disparities. Growing research suggests that psychedelic-assisted therapy (PAT) is an effective treatment for post-traumatic stress disorder and depression. It is important to understand perceptions of PAT among populations with unmet mental health needs.</p><p><strong>Methods: </strong>We conducted four focus groups to understand perceptions of psychedelic therapy within a low-income, Black, urban population.</p><p><strong>Methods: </strong>Three main themes were identified using an inductive thematic analysis approach: (1) informed hesitation mixed with increasing openness; (2) trust, autonomy, and choice; and (3) practical solutions to increase accessibility.</p><p><strong>Conclusions: </strong>Participants described many concerns related to legacies of racism in healthcare, research, drug prescription, and criminalization. Healthcare systems must invest in trust building with Black Americans to adequately meet healthcare needs. Participants emphasized ways of building trust through supporting autonomy and choice, investing in community building and agency, and suggestions to address barriers (e.g., providing childcare, providing transportation). These findings support calls to center the needs of Black American people given the lack of culturally salient therapeutic paradigms specifically for Black Americans utilized within PAT, improve access and address barriers to healthcare for Black Americans, and increase the quality of care available.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 2","pages":"103-112"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress.","authors":"Sean M Viña","doi":"10.1089/psymed.2024.0021","DOIUrl":"10.1089/psymed.2024.0021","url":null,"abstract":"<p><strong>Objective: </strong>Prior research has found an association between psychedelic use and reduced stigma attached to mental illness. However, whether psychedelics alleviate stigma-related distress remains unclear. Since stigma impacts different groups uniquely, any moderating effect of psychedelics on stigma-related distress is likely to vary across subpopulations. This study addresses two main questions: (1) Do psychedelics moderate the relationship between stigma and distress? and (2) does this relationship vary by gender and race/ethnicity? By exploring these questions, this research seeks to contribute to our understanding of psychedelic use and its impact on mental health across diverse populations.</p><p><strong>Methods: </strong>Data from the National Survey of Drug Use (2008-2019) were analyzed, with a weighted sample of 458,372. The main analysis used regression models in Stata 18 to examine the associations between lifetime psychedelic use (LPU) (psilocybin, lysergic acid diethylamide [LSD], N,N-dimethyltryptamine, peyote/mescaline, ayahuasca, and 3,4-Methylenedioxymethamphetamine), stigma attached to seeking mental health care, and psychological distress. This analysis examines whether the association between stigma and distress differs by gender, race/ethnicity, and psychedelic use (i.e., White men, White women, Black men, Black women, Asian men, Asian women, Hispanic men, and Hispanic women).</p><p><strong>Results: </strong>Results indicate that men report lower perceived stigma than women, while women report higher distress. White, Black, and Hispanic women report the highest stigma levels. Regression analysis suggests that among the total population, stigma is statistically associated with higher distress, and interaction terms indicate that MDMA, psilocybin, LSD, and LPU are linked to variations in this relationship. Regression models stratified by gender and race/ethnicity suggest that while LPU, LSD, and DMT were statistically associated with differences in the relationship between stigma and distress for White men, these associations appeared weaker for other groups.</p><p><strong>Conclusion: </strong>Psychedelic use is associated with lower reported distress from internalized stigma, though the directionality and mechanisms underlying this association remain unclear. Further research should be conducted to investigate how psychedelics can be integrated into comprehensive health treatment programs outside of psychedelics-assisted therapy. However, it is worth noting that individuals from gender and racial/ethnic minority groups may not experience the same level of benefits, suggesting other strategies may be necessary to address the stigma experienced by different groups.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 2","pages":"71-80"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Participants' Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis.","authors":"Nadav Liam Modlin, Tyler McPhee, Nira Zazon, Maria Sarang, Rebecca Hignett, Susannah Pick, Anthony Cleare, Victoria Williamson, James Rucker","doi":"10.1089/psymed.2024.0027","DOIUrl":"10.1089/psymed.2024.0027","url":null,"abstract":"<p><strong>Background: </strong>Psychedelics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine are increasingly recognized for their potential therapeutic benefits in treating complex and chronic mental health conditions. Growing public interest in psychedelics may drive increased consumption outside of medically supervised clinical trials. Correspondingly, legality issues and potential risks of unregulated use underscore the need for structured aftercare support, including psychedelic integration groups, to reduce harm potential.</p><p><strong>Methods: </strong>This study utilized a cross-sectional, observational, online, anonymous survey with 65 participants who used psychedelics and attended psychedelic integration groups. Participants provided qualitative data on their experiences via open-ended questions. Employing a deliberate analytic strategy, responses were subsequently analyzed using thematic analysis to identify key patterns and themes.</p><p><strong>Results: </strong>Three primary themes and associated subthemes emerged from the data: (1) reasons for attending psychedelic integration groups, (2) utility of psychedelic integration groups, and (3) adverse factors influencing participants' experience of the group.</p><p><strong>Discussion: </strong>The study underscores the therapeutic potential of psychedelic integration groups in providing essential community support and facilitating the processing of psychedelic experiences. However, it also highlights significant challenges, such as managing group dynamics and ensuring facilitators are adequately trained. These findings suggest that while integration groups can mitigate some risks associated with psychedelic use, research is needed to optimize their structure and effectiveness. Specifically, future studies should explore the development of standardized protocols and facilitator training programs to enhance the safety and efficacy of these groups. This research is crucial to inform policy and practice, ensuring that individuals seeking integration support and aftercare following psychedelic use have access to well-designed and delivered interventions.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 1","pages":"19-30"},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users.","authors":"Daniel J Kruger, Jacob S Aday, Christopher W Fields, Nicholas Kolbman, Nicolas Glynos, Julie Barron, Moss Herberholz, Kevin F Boehnke","doi":"10.1089/psymed.2024.0011","DOIUrl":"10.1089/psymed.2024.0011","url":null,"abstract":"<p><strong>Introduction: </strong>Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy. There is a surge of interest in psychedelics, and psychedelic-assisted psychotherapy is becoming increasingly accessible. However, most individuals using psychedelics do so outside of therapeutic contexts. It is important to understand the adverse experiences that may occur with psychedelic use, as well as adverse events that may happen even in therapeutic contexts.</p><p><strong>Materials and methods: </strong>We conducted an anonymous online survey of individuals who self-reported past psychedelic use. We asked about the frequency of experiencing 12 different adverse experiences when using psychedelics, and if they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner. Participants could also describe other adverse experiences.</p><p><strong>Results: </strong>Among 1,221 participants, most reported having adverse experiences such as being frightened (74.3%), sadness (58.6%), feeling their body shake or tremble (54.3%), and loneliness (51.6%) during their psychedelic experiences. About half of participants reported having some other adverse experience, and one in ten participants had adverse physical reactions. About one-third of participants knew someone who was arrested for possession or use of psychedelics; 8% reported that they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner; and one-quarter of participants knew someone who experienced a severe adverse event other than inappropriate sexual contact or arrest.</p><p><strong>Conclusion: </strong>Despite beneficial effects, psychedelic experiences can also be challenging, distressing, or even harmful. Adverse events can increase the risks of psychological harm, legal problems, stigma, and public health issues. Therefore, it is essential to prevent, identify, manage, and treat adverse events during psychedelic experiences to ensure the safety and well-being of the participants and the facilitators, and create opportunities for \"integration\" even with unguided sessions.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 1","pages":"41-47"},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder.","authors":"Noah D Gold, Broc A Pagni, Petros D Petridis, Michael P Bogenschutz","doi":"10.1089/psymed.2024.0030","DOIUrl":"10.1089/psymed.2024.0030","url":null,"abstract":"<p><strong>Background: </strong>Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is being actively studied for various psychiatric conditions, its effects on personal values in patients with alcohol use disorder (AUD) remain unexplored. This study examined the effects of PAT on personal values in patients with AUD and assessed relationships between value changes, acute psilocybin experiences, and drinking outcomes.</p><p><strong>Methods: </strong>In a phase II clinical trial (NCT02061293), 93 participants with AUD received 12 weeks of treatment, including manualized psychotherapy and two 8-h drug administration sessions with either psilocybin (<i>n</i> = 48) or active placebo (<i>n</i> = 45). Personal values were assessed before and after treatment using the Schwartz Value Survey (SVS), which includes 4 domain scores (Openness to Change, Self-Enhancement, Conservation, Self-Transcendence) and 10 subscales. The acute psychedelic experience was measured using the 30-item Mystical Experience Questionnaire (MEQ) and the 5-Dimensional Altered States of Consciousness Scale (5D-ASC). Treatment effects were assessed using univariate ANCOVAs, with baseline SVS values as covariates. Time effects within each group were evaluated using paired <i>t</i>-tests. Pearson correlations examined the relationship between value changes and acute effects, and also value changes and drinking outcomes.</p><p><strong>Results: </strong>Significant treatment effects were detected for the Conservation domain and its subscales \"security\" and \"tradition.\" No other domains or subscales showed significant treatment effects. Within the psilocybin group, time effects were significant only for conservation, and its subscales \"tradition,\" and \"security\". No significant time effects were detected in the placebo group. In the psilocybin group, the MEQ subscale Ineffability was significantly associated with increases in Conservation, \"security,\" and \"tradition\" (<i>r</i> = 0.31-0.34). 5D-ASC subscale Vigilance Reduction was associated with Conservation (<i>r</i> = 0.31), but not its subscales. 5D-ASC subscale Dread of Ego Dissolution during the psilocybin sessions correlated with increases in \"tradition\" (<i>r</i> = 0.31). None of the value changes were significantly associated with drinking outcomes.</p><p><strong>Conclusion: </strong>PAT may alter value structure in patients with AUD patients by increasing Conservation. Although some associations were found between acute psychedelic effects and changes in Conservation, these value changes were not related to drinking outcomes.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 1","pages":"31-40"},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Events Should Not Be Surprising in Psychedelic Research.","authors":"Rebecca Ehrenkranz, Manish Agrawal, Sandeep M Nayak, David B Yaden","doi":"10.1089/psymed.2024.0006","DOIUrl":"10.1089/psymed.2024.0006","url":null,"abstract":"<p><p>Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In recent years, the public discourse around psychedelic treatments has been largely positive and focused on benefits more than risks. We believe the field would benefit from more balanced attention to the risks as well as benefits of psychedelics within the scientific community and broader public. Coverage of psychedelic science has swung between a pendulum of extremes, from fearmongering in past decades to effusive optimism today. Public discourse about the risks and benefits of psychedelics can and should instead be grounded in the growing evidence from clinical trials as well as participant reports. While most adverse events related to pyschedelics are mild, some have been severe and serious, and public education about the existence and nature of those risks is necessary. We predict that as more studies are conducted and eligibility criteria are relaxed to improve access, the incidence and severity of adverse events will increase. While no medical intervention is risk-free, it will be increasingly important to quantify and effectively communicate the risk/benefit profile of psychedelics.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"3 1","pages":"59-62"},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}